Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Inflammatory Bowel Diseases

  Free Subscription


23.04.2018

6 Aliment Pharmacol Ther
1 Dig Dis Sci
1 Dis Colon Rectum
1 Gastroenterology
14 Inflamm Bowel Dis
1 J Crohns Colitis
1 J Gastroenterol
1 J Pediatr
1 Proc Natl Acad Sci U S A


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Aliment Pharmacol Ther

  1. PAVLIDIS P, Graham J, Gulati S, Dubois P, et al
    Letter: vedolizumab for autoimmune liver disease associated inflammatory bowel disease.
    Aliment Pharmacol Ther. 2018;47:1422-1423.
    PubMed     Text format    

  2. MANOSA M, Domenech E
    Letter: phenotype and natural history of elderly onset inflammatory bowel disease-Authors' reply.
    Aliment Pharmacol Ther. 2018;47:1421-1422.
    PubMed     Text format    

  3. CHRISTENSEN B, Gibson PR, Rubin DT
    Letter: vedolizumab for autoimmune liver disease associated inflammatory bowel disease-Authors' reply.
    Aliment Pharmacol Ther. 2018;47:1423-1424.
    PubMed     Text format    

  4. EVERHOV AH, Ludvigsson JF, Olen O
    Letter: phenotype and natural history of elderly onset inflammatory bowel disease.
    Aliment Pharmacol Ther. 2018;47:1420-1421.
    PubMed     Text format    

  5. WHITE JR, Phillips F, Monaghan T, Fateen W, et al
    Review article: novel oral-targeted therapies in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2018 Apr 19. doi: 10.1111/apt.14669.
    PubMed     Text format     Abstract available

  6. KURNOOL S, Nguyen NH, Proudfoot J, Dulai PS, et al
    High body mass index is associated with increased risk of treatment failure and surgery in biologic-treated patients with ulcerative colitis.
    Aliment Pharmacol Ther. 2018 Apr 17. doi: 10.1111/apt.14665.
    PubMed     Text format     Abstract available


    Dig Dis Sci

  7. SHAH R, Ho EY, Kramer JR, Richardson P, et al
    Hepatitis B Virus Screening and Reactivation in a National VA Cohort of Patients with Inflammatory Bowel Disease Treated with Tumor Necrosis Factor Antagonists.
    Dig Dis Sci. 2018 Apr 16. pii: 10.1007/s10620-018-5042.
    PubMed     Text format     Abstract available


    Dis Colon Rectum

  8. LANDISCH RM, Knechtges PM, Otterson MF, Ludwig KA, et al
    Pouch Volvulus in Patients Having Undergone Restorative Proctocolectomy for Ulcerative Colitis: A Case Series.
    Dis Colon Rectum. 2018 Apr 16. doi: 10.1097/DCR.0000000000001050.
    PubMed     Text format     Abstract available


    Gastroenterology

  9. FEAGAN BG, Sands BE, Rossiter G, Li X, et al
    Effects of Mongersen (GED-0301) on Endoscopic and Clinical Outcomes in Patients With Active Crohn's Disease.
    Gastroenterology. 2018;154:61-64.
    PubMed     Text format     Abstract available


    Inflamm Bowel Dis

  10. MARK-CHRISTENSEN A, Laurberg S, Haboubi N
    Dysplasia in Inflammatory Bowel Disease: Historical Review, Critical Histopathological Analysis, and Clinical Implications.
    Inflamm Bowel Dis. 2018 Apr 13. pii: 4969836. doi: 10.1093.
    PubMed     Text format     Abstract available

  11. BUER LCT, Hoivik ML, Warren DJ, Medhus AW, et al
    Combining Anti-TNF-alpha and Vedolizumab in the Treatment of Inflammatory Bowel Disease: A Case Series.
    Inflamm Bowel Dis. 2018 Apr 12. pii: 4969708. doi: 10.1093.
    PubMed     Text format     Abstract available

  12. BERNSTEIN CN, Zhang L, Lix LM, Graff LA, et al
    The Validity and Reliability of Screening Measures for Depression and Anxiety Disorders in Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2018 Apr 13. pii: 4969741. doi: 10.1093.
    PubMed     Text format     Abstract available

  13. DUBINSKY MC, Cross RK, Sandborn WJ, Long M, et al
    Extraintestinal Manifestations in Vedolizumab and Anti-TNF-Treated Patients With Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2018 Apr 13. pii: 4969986. doi: 10.1093.
    PubMed     Text format     Abstract available

  14. WENTWORTH BJ, Buerlein RCD, Tuskey AG, Overby MA, et al
    Nonadherence to Biologic Therapies in Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2018 Apr 13. pii: 4969742. doi: 10.1093.
    PubMed     Text format     Abstract available

  15. FLYNN AD, Valentine JF
    Chromoendoscopy for Dysplasia Surveillance in Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2018 Apr 13. pii: 4969996. doi: 10.1093.
    PubMed     Text format     Abstract available

  16. VAN DE VONDEL S, Baert F, Reenaers C, Vanden Branden S, et al
    Incidence and Predictors of Success of Adalimumab Dose Escalation and De-escalation in Ulcerative Colitis: a Real-World Belgian Cohort Study.
    Inflamm Bowel Dis. 2018 Apr 13. pii: 4969974. doi: 10.1093.
    PubMed     Text format     Abstract available

  17. HOSOMI S, Watanabe K, Nishida Y, Yamagami H, et al
    Combined Infection of Human Herpes Viruses: A Risk Factor for Subsequent Colectomy in Ulcerative Colitis.
    Inflamm Bowel Dis. 2018 Apr 13. pii: 4969863. doi: 10.1093.
    PubMed     Text format     Abstract available

  18. AKHUEMONKHAN E, Parian A, Carson KA, Hutfless S, et al
    Adverse Reactions After Intravenous Iron Infusion Among Inflammatory Bowel Disease Patients in the United States, 2010-2014.
    Inflamm Bowel Dis. 2018 Apr 13. pii: 4969822. doi: 10.1093.
    PubMed     Text format     Abstract available

  19. MEIJER B, Mulder CJJ, Bouma G, Ponsioen CY, et al
    Methotrexate and Thioguanine Rescue Therapy for Conventional Thiopurine Failing Ulcerative Colitis Patients: A Multi-center Database Study on Tolerability and Effectiveness.
    Inflamm Bowel Dis. 2018 Apr 13. pii: 4969999. doi: 10.1093.
    PubMed     Text format     Abstract available

  20. AUTH MK, Bunn SK, Protheroe AL, Williams LJ, et al
    Improved Medical Treatment and Surgical Surveillance of Children and Adolescents with Ulcerative Colitis in the United Kingdom.
    Inflamm Bowel Dis. 2018 Apr 13. pii: 4969914. doi: 10.1093.
    PubMed     Text format     Abstract available

  21. GULATI S, Emmanuel A, Burt M, Dubois P, et al
    Outcomes of Endoscopic Resections of Large Laterally Spreading Colorectal Lesions in Inflammatory Bowel Disease: a Single United Kingdom Center Experience.
    Inflamm Bowel Dis. 2018 Apr 13. pii: 4969983. doi: 10.1093.
    PubMed     Text format     Abstract available

  22. SHUTKEVER O, Gracie DJ, Young C, Wood HM, et al
    No Significant Association Between the Fecal Microbiome and the Presence of Irritable Bowel Syndrome-type Symptoms in Patients with Quiescent Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2018 Apr 13. pii: 4970060. doi: 10.1093.
    PubMed     Text format     Abstract available

  23. CARD T, Xu J, Liang H, Bhayat F, et al
    What Is the Risk of Progressive Multifocal Leukoencephalopathy in Patients With Ulcerative Colitis or Crohn's Disease Treated With Vedolizumab?
    Inflamm Bowel Dis. 2018 Apr 13. pii: 4969878. doi: 10.1093.
    PubMed     Text format     Abstract available


    J Crohns Colitis

  24. KEVANS D, Murthy S, Mould DR, Silverberg MS, et al
    Accelerated Clearance of Infliximab is Associated With Treatment Failure in Patients With Corticosteroid-Refractory Acute Ulcerative Colitis.
    J Crohns Colitis. 2018 Apr 6. pii: 4963864. doi: 10.1093.
    PubMed     Text format     Abstract available


    J Gastroenterol

  25. NAKAZAWA T, Notohara K, Tazuma S, Tanaka A, et al
    The 2016 diagnostic criteria for primary sclerosing cholangitis.
    J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


    J Pediatr

  26. HOFFENBERG EJ, McWilliams SK, Mikulich-Gilbertson SK, Murphy BV, et al
    Marijuana Use by Adolescents and Young Adults with Inflammatory Bowel Disease.
    J Pediatr. 2018 Apr 16. pii: S0022-3476(18)30388.
    PubMed     Text format     Abstract available


    Proc Natl Acad Sci U S A

  27. CHAO KL, Kulakova L, Herzberg O
    Gene polymorphism linked to increased asthma and IBD risk alters gasdermin-B structure, a sulfatide and phosphoinositide binding protein.
    Proc Natl Acad Sci U S A. 2017 Feb 1. pii: 201616783.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Inflammatory Bowel Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: